Long-term Effect of Sacubitril/valsartan Use on Uric Acid Levels in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction

Background: Heart failure with reduced ejection fraction (HFrEF), characterized by neurohormonal activation and metabolic dysregulation, may lead to elevated serum uric acid (SUA) levels.Although the sacubitril/valsartan (S/V) molecule confers notable cardiovascular benefits and has been observed to influence multiple metabolic parameters, its impact on SUA levels remains incompletely elucidated. Aim:To investigate the long-term impact of the S/V combination on SUA levels in patients with HFrEF. Study Design: Longitudinal retrospective cohort study.Methods: For this single-center, retrospective, cross-sectional analysis, data from patients using S/V for HFrEF were collected from their medical records.In addition to the routine controls, the uric acid levels of patients were measured at the baseline and in the first and second years of their treatment.The parameters obtained at two years included the serum uric acid (SUA) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.The SUA and NT-proBNP levels measured in the first and second years were compared with the baseline value.Results: A total of 148 patients with a functional capacity in New York Heart Association II-IV and those who were using S/V due to HFrEF were included in this study.The mean age of the study patients was 66.610.3years, and 61.5% of them were male.The baseline SUA levels were 6.61.6, which reduced to 6.21.8 at the end of the first year and to 61.6 at the end of the second year (p<0.001).